Glen Clova Scientific is pioneering a new generation of Active Biologic drugs aimed at enhancing patient treatment options for chronic diseases. Their innovative approach focuses on developing biologics that enable patients to generate natural antibodies against harmful targets, thereby improving accessibility to high-quality treatments. The company addresses the limitations of conventional biologic drugs, such as frequent dosing and high manufacturing costs, by introducing a new class of Active Biologics that require significantly fewer doses and lower quantities of drug per administration. This not only enhances the pharmacoeconomics of treatment but also reduces the need for extensive safety monitoring, making it feasible to implement these therapies in markets with limited healthcare infrastructure.

The core technology behind Glen Clova Scientific's Active Biologics involves a proprietary virus-like particle (VLP) scaffold combined with chaperone-assisted epitope proteins. This unique design allows for the stable auto-assembly of VLPs, which can display various epitope proteins without the need for genetic fusion or chemical linkage. The process is streamlined through a generic purification scheme applicable to any displayed protein, ensuring cost efficiency and maximal immunogenicity. Currently, the company has three programs in pre-clinical development targeting conditions such as senile pruritus, atopic dermatitis, and asthma, all selected based on validated safety and efficacy data from existing biologic drugs.

United Kingdom

Glen Clova Scientific Ltd (GCS) is developing a new generation of Active Biologics to treat inflammatory conditions. 

We are an ambitious spinout from the University of Dundee aiming to address the global need to make effective treatments available for millions of patients. Our novel Virus-Like-Particle technology is poised to address inherent limitations of the current blockbuster class of Biologic drugs. 

Our vision is to make high end biotech pharmaceuticals much more accessible to patients than current blockbusters. 

#Glenclovascientific #Dundee

Glen Clova Scientific

Company Details